Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting

Novo has “gone shopping” to fill pipeline gaps, with a focus on obesity and diabetes, plus an expansion in blood and endocrine disorders, liver diseases and cardiovascular conditions.